Medical network - December 21, the old pattern is broken, the new pattern has not been formed. In 2016 Chinese medical market under pressure from policy adjustment, such as the economic downturn many difficult, industry growth and profit still keep rising. With innovation, overseas capital market strategy and transformation for key points. China's pharmaceutical industry information center consulting director and chief consultant Lu Minli in the 76th session of the national drug trade fair analysis of the current situation of China pharmaceutical market in 2016, and put forward our country medicine industry in 2017 will finish more quality growth.
Pharmaceutical industry keep future economic growth
Early Lu Minli introduction, "much starker choices-and graver consequences-in", China's pharmaceutical industry keep the steady development of economy of scale, main business revenue and profit growth. Pharmaceutical industry enterprises in 2016 main business income of nearly three trillion yuan, is expected to reach 3.2 trillion yuan in 2017; And corporate profit in the pharmaceutical industry will continue to improve, and in 2017 reached 368.6 billion yuan.
At the same time, in the pharmaceutical industry in China has experienced over the past few years after the industrial upgrading of labor, both revenue growth and profit growth, compared with the past two years have a rebound, expected in 2017 will further enhance its growth. In 2016, the pharmaceutical industry enterprise main business revenue growth of 10.3%, total profit growth of 15.6%. In 2017 to 10.5% and 10.5% respectively.
Transfer to grassroots market segments: sales terminal
Lu Minli said, the layout of the pharmaceutical market in China follow the policy changes, to adjust the social development. The latest data analysis in 2015, with sales center segment of the market and found that the main body in the core of the medical market, for large medical institutions accounted for about 63%, followed by the second terminal is a pharmacy market, accounting for more than 17%; The third terminal and the broad market of primary care, accounted for 20%. At present, slow disease, common disease treatment center gradually transferred to the grassroots market, so primary market will be the future pharmaceutical enterprise layout is the focus of the market, the proportion will gradually increase in the future.
With drug type market segment, Chinese pharmaceutical chemicals sales accounted for the highest on the market, even greater than the sum of proprietary Chinese medicine and biological drug sales. The drugs market sales of 1.3 trillion in 2015, including chemical medicine preparations sales of 888 billion yuan, accounts for about 66.5% of the total domestic pharmaceutical market; Biological pharmaceutical sales of 109.5 billion yuan, accounting for 8.2% of the total market. Proprietary Chinese medicine market size is about 337.9 billion yuan, accounting for 25.3% of the total market.
In industry enterprise type market segment, proprietary Chinese medicine the most number of companies as the main products, achieve more than one-third of the market. According to statistics, China's pharmaceutical industry information center is currently the country there are about 5065 drug substances and drug products production enterprises, the main products are active pharmaceutical ingredients, the number of Chinese medicines, chemical, and biological drugs accounted for 25.6%, 22.4%, 32.7% and 22.4% respectively, the top still for proprietary Chinese medicine preparations and chemical medicine, active pharmaceutical ingredients.
In 2015, according to therapeutic area segmentation, drug market in China is the most important component for anti-infection drugs medication, antitumor drugs, cardiovascular system, nervous system drugs and digestive system drugs five areas. According to statistics, China's pharmaceutical industry information center five drugs in the size of the sample hospital drug market in China accounted for 12.57%, 12.52% and 10.02% respectively, 9.08% and 8.59%.
The pharmaceutical industry regulations tighter The product cost will increase
Lu Minli believe that drug is prevention cure of special goods, so the pharmaceutical industry each link is affected by policies and regulations are larger. Research and development, chemical medicine preparations, the adjustment of classification, clinical data assets check, the evaluation of generic drugs, adjustment of urgent clinical needs products, medicinal contain excipients and medicinal management approval notice will affect the whole medicine market. Policy, health care reform gradually promote grassroots medical ability, encourage social do medical, drug zero bonus and propulsion control medicine accounted for a number of measures such as changes in drug market structure.
In 2016 the development of Chinese pharmaceutical market has a number of drivers:
1, the rigid demand increasing. Ageing population growth, chronic diseases increase in the number, speed up urbanization process, rural grassroots medical demand and a series of changes, belong to the rigid demand of the development of medicine industry, it will make the entire medical market expanding growth.
2, to enhance the ability to pay. At present China's medical security system coverage has reached more than 95%, the per capita medical security efforts, the people's health consciousness and enhanced the ability of disease burden, make the whole crowd health to further improve the ability to pay.
3, increasing investment in health care. In 2015 the total health expenses exceed 4 trillion nationwide, a percentage of GDP is 6.0%, the government's increasing of medical and health care investment become the important driving factor of market development.
4, macro policy dividends. "Healthy China" has become a national strategy, the construction of medical health industry to national level. In addition, the "made in China 2025" in the field of important development direction, the pharmaceutical industry "much starker choices-and graver consequences-in" development planning of key development fields are pointed out the direction for the development of the whole pharmaceutical industry.
But in front of opportunity, medical market development also faces many challenges:
1, the macroeconomic impact. In 2015 China's GDP growth of 6.9%, has fallen to below 7%, drug market scale growth is only 7.87%, at the same time on the surface of medical market growth is higher than GDP growth, but the macroeconomic environment in can cause great influence to the entire medical market.
2, industry standard and stricter regulation, the product cost increase. 2015 edition of "Chinese pharmacopoeia" and "drug registration management measure (revised) are specified, the original medicine and the concept of generic drugs will disappeared, replaced by the" new world "concept, and all improved formulations of products must be the shortage of clinical and production products. Increasing production process inspection requirements and drug approval for examination and approval of the comprehensive reform of showing the change trend of pharmaceutical industry standards and regulation increasingly strict, pharmaceutical production costs will increase.
3, drug procurement and price management mechanism for the market pressure. China's latest determine drug bidding procurement methods, cancel the highest drug retail price regulation, make the drug price control pressure is growing. Drug purchase and price management mechanisms for the pharmaceutical industry development will also be a new important impact. Recently, people club department officials said, the future companies in the fields of both a treatment by consistent evaluation of generic drugs, make payment standard will be known as the standard, namely the original drugs and generic drugs will stand on the same starting line, the difference only lies in the commodity brand.
Market structure reform to planning enterprise multiple cooperation against risk
Lu Minli concluded, the future development trend of China's pharmaceutical market growth can be summarized as four key points, optimization, integration, supervision.
A new era of growth, policy, aging will continue to be positive factors, such as pharmaceutical industry, appeared more innovative medicines and medical policy will also be more stimulate the growth of the industry.
New optimization, reform thorough, the grading system gradually, grassroots medical market gradually strengthen, affect drug terminal market structure. Grassroots layout retail channels will become the future direction of medical market, many large foreign pharmaceutical companies such as sanofi, astrazeneca have begun layout grassroots market, a medical representative for basic-level hospital visit will be more frequent.
Integration of new era, the pharmaceutical industry will be further integration, mergers and acquisitions will be increased year by year, quantity and amount for drug firms breakneck expansion of cooperation, cooperation between state-owned enterprises, foreign enterprises and capital more diversified in form, through the establishment of more large-scale financial entities, control costs, to resist risks.
New regulatory era, the pharmaceutical industry will be further enhanced, to further improve market access status, leads to the transformation of the industry reshuffle and enterprise. |
